Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
Year: 2021
Type: article
Source: Annals of Oncology
Authors: R.V. Rawson, C. Adhikari, C. Bierman, S.N. Lo, E. Shklovskaya, E.A. Rozeman, A.M. Menzies, A.C.J. van Akkooi, K.F. Shannon, M. Gonzalez, A.D. Guminski, M.T. Tetzlaff, J.R. Stretch, H. Eriksson, J.V. van Thienen, M.W. Wouters, J.B.A.G. Haanen, W.M.C. Klop, C.L. Zuur, W.J. van Houdt, O.E. Nieweg, S. Ch'ng, H. Rizos, R.P.M. Saw, A.J. Spillane, J.S. Wilmott, C.U. Blank, G.V. Long, B.A. van de Wiel, R.A. Scolyer
Institutions: The University of Sydney, Royal Prince Alfred Hospital, Melanoma Institute Australia, NSW Health Pathology, The Netherlands Cancer Institute, Macquarie University, Royal North Shore Hospital, University of California, San Francisco, Karolinska University Hospital, Karolinska Institutet, Leiden University Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Stryker, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Myriad Genetics, Cancer Institute NSW, University of Sydney, Sun Pharma, Melanoma Institute Australia, Qbiotics, Medical Research Council, National Health and Medical Research Council
OpenAlex ID: W3136029599